Detalles de la búsqueda
1.
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
Blood;
123(4): 554-61, 2014 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24311721
2.
Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330.
Haematologica;
104(2): e59-e62, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30115657
3.
Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group.
Am J Hematol;
88(8): 694-702, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23686445
4.
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.
Nat Commun;
13(1): 1790, 2022 04 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35379805
5.
ICOSL+ plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist.
Sci Transl Med;
12(564)2020 10 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33028709
6.
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
Clin Cancer Res;
22(23): 5829-5838, 2016 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27189165
7.
Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.
Oncotarget;
7(28): 43281-43294, 2016 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27248327
8.
The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
PLoS One;
10(8): e0135945, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26305211
9.
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
J Hematol Oncol;
8: 115, 2015 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-26487643
10.
Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Clin Cancer Res;
21(14): 3187-95, 2015 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25825478
11.
High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Leuk Lymphoma;
55(12): 2817-21, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24559289
12.
COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.
Leukemia;
33(3): 805-808, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30206306
13.
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.
Leukemia;
32(5): 1239-1243, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29588544
14.
AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.
PLoS One;
8(1): e53518, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23320091
15.
Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
J Hematol Oncol;
9(1): 133, 2016 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-27903291
16.
High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Leuk Lymphoma;
54(1): 202-4, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22680764
Resultados
1 -
16
de 16
1
Próxima >
>>